85

Last update : 01/01/2019

ASSESS - Assessment of Systemic Involvement and Progression for Patients with Primary Sjogren's Syndrome

Head : Gottenberg Jacques-Eric, U1109 Immuno-rhumatologie moléculaire

Main objective

To prospectively determine for the first time the prevalence and risk factors for systemic complications and lymphoma in primary Sjögren's syndrome.

Inclusion criteria

- Men or women - adults - patients in tertiary centres for autoimmune diseases

Last update : 01/01/2019

ADEOS - Adherence evaluation of osteoporosis treatment

Head : Leclerc-Zwirn Christel, Laboratoire GSK

Version 1

86

Last update : 01/01/2018

ADEOS - Adherence evaluation of osteoporosis treatment

Head : Leclerc-Zwirn Christel, Laboratoire GSK

Main objective

Finalize and validate a self-administered instrument developed to evaluate adhesion to the treatment
of postmenopausal osteoporosis

Inclusion criteria

Woman;
Over the age of 50 years;
Patient to whom has been prescribed one of the following osteoporosis treatments in the six months prior to the inclusion starting date:
bisphosphonates, selective estrogen receptor modulators (SERM), or strontium ranelate;
Patient fluent in French and who has the cognitive and functional ability required to complete
the self-questionnaires included in the study on their own;
Informed patient who has given their oral consent to participate in this study

Last update : 01/01/2018

B009 - Follow-up study of patients treated with drotrecogin alfa (activated) (Xigris®) in France

Head : Laboratoire , Eli Lilly France

Version 1

87

Last update : 01/01/2019

B009 - Follow-up study of patients treated with drotrecogin alfa (activated) (Xigris®) in France

Head : Laboratoire , Eli Lilly France

Main objective

Primary objective: evaluate 1-month mortality (at 28 days and 31 days) of patients treated with drotrecogin alpha (activated) in intensive care forsevere sepsis and describe causes of death.
Secondary objectives: characteristics of patients and conditions of use.

Inclusion criteria

All adult patients treated with drotrecogin alpha (activated) in France in the course of routine care in intensive care services.

Last update : 01/01/2019

ADHOC - Observational study on the various arrangements for caring for patients with type-2 diabetes treated by associating oral diabetes medication and insulin

Head : VIGNAL Franck, Sanofi Aventis

Version 1

88

Last update : 01/01/2018

ADHOC - Observational study on the various arrangements for caring for patients with type-2 diabetes treated by associating oral diabetes medication and insulin

Head : VIGNAL Franck, Sanofi Aventis

Main objective

Describe the various arrangements for caring for patients with type-2 diabetes treated by associating oral diabetes medication and insulin as well as their repercussion on HbA1c

Inclusion criteria

man or woman, over the age of 18 years, having type-2 diabetes treated by the association
of oral diabetes medication and insulin for at least 6 months, accepting to participate in the study

Last update : 01/01/2018

PREFACE - Study on the prevalence of facial lipoatrophy in patients infected by HIV virus receiving antiretroviral drugs - FRAN08-005

Head : Cohen-Codar Isabelle

Version 3

89

Last update : 07/01/2019

PREFACE - Study on the prevalence of facial lipoatrophy in patients infected by HIV virus receiving antiretroviral drugs - FRAN08-005

Head : Cohen-Codar Isabelle

Main objective

Describe the prevalence of the facial lipoatrophy in patients infected by HIV virus and receiving antiretroviral drugs. Describe the prevalence of lipoatrophies and lipodystrophic mixed syndromes.
Evaluate the score of quality of life, using the patients multi-dimensional auto-questionnaire and specific ABCD "Assessment of Body Change and Distress".

Inclusion criteria

Patient infected by HIV virus, receiving antiretroviral drugs for at least 1 month and coming to consultation at his usual follow-up center, during the period of the study, obtaining of the written consent for the collect and exploitation of his personal data.

Last update : 07/01/2019

Flurec - Recurring influenza virus infections and implications in terms of epidemic recurrences and pandemic risk.

Head : Carrat Fabrice, UMR-S 707 / Epidémiologie des maladies infectieuses et modélisation
De Lamballerie Xavier, UMR-D 190, Emergence des pathologies virales

Version 1

90

Last update : 01/01/2020

Flurec - Recurring influenza virus infections and implications in terms of epidemic recurrences and pandemic risk.

Head : Carrat Fabrice, UMR-S 707 / Epidémiologie des maladies infectieuses et modélisation
De Lamballerie Xavier, UMR-D 190, Emergence des pathologies virales

Main objective

To explore cross-protective immunity involving different A/H1N1 viruses (seasonal and pandemic) and the seasonal A/H3N2 virus through data gathered from this study. This study also aims to identify the epidemiological, immunological and virological factors that determine the risk of recurring influenza infections as well as characterise the population's herd immunity and its evolution.

Inclusion criteria

The "influenza" group comprises of patients enrolled after general medical consultation for influenza-like illness during seasonal epidemic. The "non-influenza" group comprises of patients enrolled after general medical consultation during seasonal epidemic for a reason other than influenza, yet that was acute in nature e.g. infectious diarrhoea, minor trauma.

Last update : 01/01/2020